ArticleThe Lancet regional health. Western Pacific2023
Validation of the general Framingham Risk Score (FRS), SCORE2, revised PCE and WHO CVD risk scores in an Asian population.
Article in The Lancet regional health. Western Pacific, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 54 citations in OpenAlex.
- Metabolic signatures and machine learning identify gut-liver-heart axis dysfunction as a potential link to major adverse cardiovascular events in coronary artery disease.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Independent external validation and head-to-head comparison of guideline-recommended CVD risk prediction models.American journal of preventive cardiology · 2026Article
- Cutoff Values of Pulse Wave Velocity Score to Estimate 10-Year Cardiovascular Disease Risk by Framingham and SCORE2 Systems.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Impact of Specific Metabolic Syndrome Combinations on Model-Estimated 10-Year Cardiovascular Risk in a Taiwanese Population.Journal of clinical medicine · 2026Article
- Diagnostic Accuracy of Cardiovascular Disease Prediction Models: A Systematic Review and Meta-Analysis of Validation Studies.Health science reports · 2026Review
- Risk prediction for individual patients and the pitfalls of selecting an optimal prediction model: do not judge a model by its c-statistic.European journal of epidemiology · 2026Article
- Mapping and evaluation of global and country-specific cardiovascular disease risk prediction models.Future cardiology · 2026Review
- Interpretable machine learning analysis of routine blood biomarkers and derived indicators for predicting coronary heart disease in patients with carotid stenosis.BMC cardiovascular disorders · 2026Article
- Is artificial intelligence a friend or foe to epidemiology?Annals of epidemiology · 2026Review
- Association between CT-based adrenal gland volume and 10-year cardiovascular disease risk in patients with diabetes mellitus.Quantitative imaging in medicine and surgery · 2026Article
- Decoding cardiovascular risk in Chinese middle-aged and elderly adults: a 9-year prospective study integrating machine learning with explainable AI based on CHARLS cohort.BMC medical informatics and decision making · 2026Article
- Factors associated with higher cardiovascular disease risk awareness among patients with cardiovascular risk factors in primary care.BMC primary care · 2026Article
- Association of Original and Revised Pooled Cohort Equations With Cardiovascular and Cerebrovascular Mortality.CNS neuroscience & therapeutics · 2026Article
- Joint Association of Cholesterol, High-Density Lipoprotein and Glucose Index, and Circadian Syndrome With Incidence of Cardiovascular Disease: Results From National Longitudinal Prospective Studies.Cardiovascular therapeutics · 2026Article
- Narrative review of the development of an ischaemic heart disease prognostic scoring tool (i-IHD score) among patients with type 2 diabetes mellitus in Malaysia.Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia · 2026Review
- A Genetic Risk Prediction Model for Coronary Artery Disease Integrating CYP17A1 Polymorphisms and Clinical Variables in a Chinese Population.International journal of general medicine · 2026Article
- Article
- Article
- Laboratory Biomarker Profiles and Phenotypic Discrimination in Coronary Artery Disease with Metabolic and Renal Comorbidities: A Cross-Sectional Study.International journal of general medicine · 2026Article
- Regional variations in cardiovascular risk predictions: a comparative analysis of Framingham, SCORE2, and WHO models across 53 countries.Journal of global health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular risk prediction models incorporate myriad CVD risk factors. Current prediction models are developed from non-Asian populations, and their utility in other parts of the world is unknown. We validated and compared the performance of CVD risk prediction models in an Asian population. Methods: Four validation groups were extracted from a longitudinal community-based study dataset of 12,573 participants aged ≥18 years to validate the Framingham Risk Score (FRS), Systematic COronary Risk Evaluation 2 (SCORE2), Revised Pooled Cohort Equations (RPCE), and World Health Organization cardiovascular disease (WHO CVD) models. Two measures of validation are examined: discrimination and calibration. Outcome of interest was 10-year risk of CVD events (fatal and non-fatal). SCORE2 and RPCE performances were compared to SCORE and PCE, respectively. Findings: FRS (AUC = 0.750) and RPCE (AUC = 0.752) showed good discrimination in CVD risk prediction. Although FRS and RPCE have poor calibration, FRS demonstrates smaller discordance for FRS vs. RPCE (298% vs. 733% in men, 146% vs. 391% in women). Other models had reasonable discrimination (AUC = 0.706-0.732). Only SCORE2-Low, -Moderate and -High (aged <50) had good calibration (X Interpretation: In Malaysians, RPCE are evaluated be the most clinically useful to predict CVD risk. Additionally, SCORE2 and RPCE outperformed SCORE and PCE, respectively. Funding: This work was supported by the Malaysian Ministry of Science, Technology, and Innovation (MOSTI) (Grant No: TDF03211036).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.